Literature DB >> 23635390

Validity of dual MRI and F-FDG PET imaging in predicting vulnerable and inflamed carotid plaque.

Hisayasu Saito1, Satoshi Kuroda, Kenji Hirata, Keiichi Magota, Tohru Shiga, Nagara Tamaki, Daisuke Yoshida, Satoshi Terae, Naoki Nakayama, Kiyohiro Houkin.   

Abstract

BACKGROUND: Vulnerable and inflamed plaques in the carotid artery are at high risk of ischemic stroke, suggesting the importance of diagnostic modalities to detect them in patients with carotid stenosis with high sensitivity and specificity. Although many investigators have reported that magnetic resonance imaging (MRI) is a useful tool to predict the vulnerable components of carotid plaque, its validity is not established. On the other hand, (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) may be an alternative modality to directly identify the inflamed plaque in carotid artery stenosis. Therefore, this study aimed at evaluating the validity of MRI and FDG-PET to predict vulnerable and inflamed carotid plaque.
METHODS: This prospective study totally included 25 patients who underwent carotid endarterectomy (CEA) for carotid artery stenosis at our institute between January 2009 and January 2012. Prior to CEA, FDG-PET, black-blood T1-weighted imaging (BB-T1WI), and 3-dimensional time-of-flight (TOF) imaging were performed. The specimens were stained with hematoxylin-eosin to assess the different plaque components (lipid, hemorrhage, calcification, and fibrous tissue). In addition, they were stained with primary antibodies against CD68 (activated macrophages) and matrix metalloproteinase (MMP)-9.
RESULTS: High FDG uptake was detected in 13 (52.0%) of 25 patients. All of them had lipid-rich plaque. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to identify the lipid-rich plaques were all 100% for FDG-PET. More importantly, all of the FDG-positive plaques had strong immunoreactivity against both CD68 and MMP-9. There was a significant correlation between the findings on FDG-PET and those on immunohistochemistry against CD68 and MMP-9 (p = 0.006 and 0.004, respectively). On the other hand, 16 (64.0%) of 25 patients had high signal intensity plaque on BB-T1WI. In 7 of these 16 patients, the lesions also showed high signal intensity on TOF imaging. All of them had a large intraplaque hemorrhage. The sensitivity, specificity, PPV, and NPV to identify a large intraplaque hemorrhage were 70, 100, 100, and 83%, respectively, for MRI.
CONCLUSIONS: These findings suggest that FDG-PET and MRI are complementary to predict high-risk carotid plaque, such as lipid-rich or hemorrhagic plaque. FDG-PET can accurately predict the lipid-rich and inflamed plaque. MRI is valuable to identify unstable plaque with a large intraplaque hemorrhage. The combination of these two modalities may play an important role in predicting carotid plaque at high risk of ischemic stroke.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635390     DOI: 10.1159/000348846

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  20 in total

1.  High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging.

Authors:  Fabien Hyafil; Andreas Schindler; Dominik Sepp; Tilman Obenhuber; Anna Bayer-Karpinska; Tobias Boeckh-Behrens; Sabine Höhn; Marcus Hacker; Stephan G Nekolla; Axel Rominger; Martin Dichgans; Markus Schwaiger; Tobias Saam; Holger Poppert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-03       Impact factor: 9.236

Review 2.  Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis.

Authors:  Mingyi Wang; Soo Hyuk Kim; Robert E Monticone; Edward G Lakatta
Journal:  Hypertension       Date:  2015-02-09       Impact factor: 10.190

Review 3.  Imaging the event-prone coronary artery plaque.

Authors:  Andreas A Giannopoulos; Dominik C Benz; Christoph Gräni; Ronny R Buechel
Journal:  J Nucl Cardiol       Date:  2017-07-06       Impact factor: 5.952

4.  Feasibility of carotid artery PET/MRI in psoriasis patients.

Authors:  Prabhakar Rajiah; Mojgan Hojjati; Ziang Lu; Vijaya Kosaraju; Sasan Partovi; James K O'Donnell; Christopher Longenecker; Grace A McComsey; Jackelyn B Golden; Fuad Muakkassa; Scott Santilli; Thomas S McCormick; Kevin D Cooper; Neil J Korman
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-08-20

5.  Carotid Plaque Positron Emission Tomography Imaging and Cerebral Ischemic Disease.

Authors:  Salama Chaker; Khalid Al-Dasuqi; Hediyeh Baradaran; Michelle Demetres; Diana Delgado; Sadek Nehmeh; Joseph R Osborne; Paul J Christos; Hooman Kamel; Ajay Gupta
Journal:  Stroke       Date:  2019-07-05       Impact factor: 7.914

6.  Imaging Immunometabolism in Atherosclerosis.

Authors:  Philip Z Mannes; Sina Tavakoli
Journal:  J Nucl Med       Date:  2021-05-07       Impact factor: 10.057

7.  Decreased ¹³N-labeled ammonia uptake in the ipsilateral and contralateral hemispheres following carotid endarterectomy.

Authors:  Tao Wang; Xuemei Wang; Yulin He; Tao Zhang; Jianqiang Song; Xia Bai; Chunlei Han
Journal:  Mol Med Rep       Date:  2015-09-09       Impact factor: 2.952

Review 8.  Imaging atherosclerosis with hybrid positron emission tomography/magnetic resonance imaging.

Authors:  Rasmus Sejersten Ripa; Andreas Kjær
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

Review 9.  Integrated cardiovascular assessment of atherosclerosis using PET/MRI.

Authors:  Nicholas R Evans; Jason M Tarkin; Elizabeth Pv Le; Rouchelle S Sriranjan; Andrej Corovic; Elizabeth A Warburton; James Hf Rudd
Journal:  Br J Radiol       Date:  2020-04-03       Impact factor: 3.039

10.  Multimodality molecular imaging: Gaining insights into the mechanisms linking chronic stress to cardiovascular disease.

Authors:  Michael T Osborne; Shady Abohashem; Hadil Zureigat; Taimur A Abbasi; Ahmed Tawakol
Journal:  J Nucl Cardiol       Date:  2020-11-17       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.